nPOC-POC Tenofovir
| Product Name | nPOC-POC Tenofovir |
|---|---|
| Alternate Names | Tenofovir Impurities, Impurities of Tenofovir |
| CAT No. | CS-O-10862 |
| CAS No. | 1217542-13-6 |
| Category | Impurities |
| Stock | IN-Stock |
| Mol. Wt. | 519.44 g/mol |
| Mol. For. | C₁₉H₃₀N₅O₁₀P |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Tenofovir |
| Purity | 99.39 |
| Therapeutic | Antiretroviral / Anti-HIV |
| Smileys | CCCOC(=O)OCOP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OCOC(=O)OC(C)C |
| Canonical Smiles | CCCOC(=O)OCOP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OCOC(=O)OC(C)C |
| InchIKey | FSHYLBFEGOTZGO-OAMPWVDCSA-N |
| Inchl | InChI=1S/C19H30N5O10P/c1-5-6-28-18(25)29-10-32-35(27,33-11-30-19(26)34-13(2)3)12-31-14(4)7-24-9-23-15-16(20)21-8-22-17(15)24/h8-9,13-14H,5-7,10-12H2,1-4H3,(H2,20,21,22)/t14-,35?/m1/s1 |
| IUPAC | [[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propyl carbonate |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
nPOC-POC Tenofovir is a novel prodrug of Tenofovir, which is an antiviral drug used for the treatment of HIV and hepatitis B. nPOC-POC Tenofovir is designed to improve the pharmacokinetics and bioavailability of the parent drug by increasing its solubility and stability in the body. The prodrug is rapidly converted to Tenofovir in the body, which then inhibits the reverse transcriptase enzyme of the virus, preventing the replication of the virus and slowing down the progression of the disease.
The chemical structure of nPOC-POC Tenofovir consists of two prodrug moieties, nPOC and POC, attached to the parent drug Tenofovir. These moieties improve the physicochemical properties of the drug by enhancing its water solubility and lipophilicity. The prodrug is metabolized by esterases in the body, releasing Tenofovir, which is then converted to its active form, Tenofovir diphosphate, inside the cells.
The usage of nPOC-POC Tenofovir is similar to that of Tenofovir, and it is administered orally as a tablet. The recommended dosage is 300 mg once daily for adults, and it is usually taken with food. The prodrug has been shown to be well-tolerated and safe in clinical trials, with no significant adverse effects reported. Its improved pharmacokinetic properties make it a promising candidate for the treatment of HIV and hepatitis B, especially in resource-limited settings where the availability of drugs with better bioavailability is limited.
Get an Instant Quote
Related Compounds
Tenofovir Disoproxil T11 Impurity | Mono-POC Ethyl Tenofovir | Tenofovir Alafenamide Racemic D Isomer | Ethyl Tenofovir Impurity | Tenofovir Impurity 35 | Tenofovir Alafenamide Glycosamine product | Tenofovir Disoproxil (S)-Isomer fumarate salt | Tenofovir Disoproxil Isopropoxycarbonyl | Desmethyl Tenofovir disoproxil | Tenofovir isomer 6&1 | Mono ester impurity (Tenofovir) | Tenofovir Disoproxil T12 Impurity | Tenofovir DP-IV | Tenofovir Alafenamide N-hydroxy methyl impurity | Tenofovir Mono POC Dimer Diethyl amine salt | Tenofovir Alafenamide Dimer impurity | Tenofovir impurity C fumarate salt | Tenofovir Impurity 39 (RRR) 2,3-dihydroxysuccinate salt | MOC-POC Tenofovir Fumarate | Tenofovir Impurity 59 | Tenofovir Impurity 98 | Tenofovir disoproxil impurity L | Diisopropyl Tenofovir Fumarate | Tenofovir diphosphate | Tenofovir Impurity 36 (RSR) 2,3-dihydroxysuccinate salt | Tenofovir Diphenyl HemiFumarate salt | TAF methyl ester | Tenofovir Disoproxil Fumarate USP RC J | Tenofovir EP Impurity C Succinate | Tenofovir Alafenamide Dimer Impurity II | Mono-POC Methyl Tenofovir Fumarate (Mixture of Diastereomers) | Tenofovir Disoproxil T5 Impurity | Tenofovir alafenamide Impurity 1 | Tenofovir Impurity 59-D6 | Tenofovir Alafenamide (RSR) Diasteroisomer | Tenofovir alafenamide impurity | Tenofovir Disoproxil Fumarate Impurity | tenofovir related impurity | Tenofovir Disoproxil T7 Impurity | Tenofovir Impurity 89 | Tenofovir alafenamide Impurity 3 | TAF Propyl ester Impurity | Tenofovir Related Compound 14 | Diethylaminocarboxymethyl POC Tenofovir Fumarate | Tenofovir alafenamide Impurity 5 | Tenofovir Alanine ester impurity | Isopropyl Tenofovir | Tenofovir alafenamide Methyl ester impurity | Tenofovir Disoproxil Dimer | Tenofovir Impurity 62 | Tenofovir Alfenamide Amadori Rearrangement product | Tenofovir disoproxil phosphate | Desmethyl Tenofovir Disoproxil Fumarate | Tenofovir alafenamide Impurity 2 | Mono-POC Isopropyl Tenofovir | Tenofovir Mixed dimer | MOC-POC Tenofovir | Tenofovir Mono-POC methyl ester | Tenofovir Isopropyl Carbamate | nPOC-POC Tenofovir Fumarate | TAF SRS diastereomer | Tenofovir Related Compound 5 | Tenofovir DP-V | Tenofovir Bis ((R)-9-(2-Hydroxypropyl)adenine) dimer Acetate salt | Tenofovir alafenamide (RRS) diasteroisomer | Tenofovir Alafenamide fumarate | Mono poc-isopropyl-Tenofovir fumarate salt | Tenofovir Disoproxil T8 Impurity | Tenofovir Alafenamide Enantiomer | Tenofovir Monomethyl Ester |